John Mendelsohn, president emeritus of MD Anderson Cancer Center and an elder statesman in oncology, died Jan. 7 at his home in Houston. He was 82.
I was heartbroken to learn of the passing of my mentor, colleague, and friend, Waun Ki Hong. Dr. Hong was the quintessential physician scientist who specialized in all aspects of medicine, but most notably patient care, research, and education. This is a devastating loss for the entire oncology community, and especially for all of the patients he cared for and helped.
This week, we lost a cancer research pioneer, and friend and mentor to many in the field, with the sudden death of Waun Ki Hong, M.D., a world-renowned clinical researcher who leaves behind a remarkable legacy.
Waun Ki Hong, M.D., F.A.C.P., D.M.Sc.(Hon.), Head, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, October 22, 2013. For Messenger- First Person.Yesterday, I received a succession of phone calls through the afternoon and evening—from Roy Herbst, chief of medical oncology at the Yale Cancer Center, Marge Foti, president of the American Association for Cancer Research, Patrick Hwu, head of the Division of Cancer Medicine at the MD Anderson Cancer Center (MDACC), and Otis Brawley, professor of oncology at Johns Hopkins University.
FDA has created a framework for evaluating the use of real-world evidence to support additional indications for already approved drugs as well as to satisfy drug post-marketing study requirements.
We thought you might want to see what your colleagues in oncology have been reading. So, we went through our analytics to bring you a list of 25 of The Cancer Letter's most-read stories of 2018.
Amy Abernethy, a thought leader in the field of evidence generation and the development of real-world evidence, was named principal deputy commissioner at FDA.
Breast cancer research is big business. And the incentives in that business are designed to benefit industry, doctors and institutions, leaving patients behind. In 2018 alone, about $1 billion federal dollars were invested in institutions around the country to fund research.
Around March, my friend Howard Ozer told me he was heading out on a safari. He did these things often, adding to his collection of trophies.
Charles A. Coltman Jr., a pioneer of treatment of leukemia and lymphoma, a long-time chair of SWOG, and a co-founder of the San Antonio Breast Cancer Symposium, died after a long illness on Nov. 28. He was 88.
